• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Page 4 > Press

Press releases

Page 4 > Press

Press releases

filters

Type & Disease
Topic
Location
Date Range
Type & Disease

By Type

news type

By Disease

diseases

Topic

By Topic

topic type

Location

By Location

location-news

Date Range

By Year

date range filter – slider
1999 — 2026

Results

No results found. Please try using different filter option(s).

Times of India logo
In the media
24 Apr 2026

Dengue treatments in 2-3 years, but cases set to rise with climate change

Times of India
The New Indian Express logo
In the media
23 Apr 2026

India eyes dengue treatment rollout within five years as vaccine pipeline advances

The New Indian Express
El Mundo logo
In the media
26 Mar 2026

Un golpe de efecto para acabar con la enfermedad del sueño: “Aspiramos a eliminar el trastorno en 2030”

El Mundo
RNE logo
In the media
2 Apr 2026

La milagrosa cura de la enfermedad del sueño

RTVE
Stories

Lab lessons that matter: Pharmacy students help bridge the gap in research for neglected diseases

Stories
16 Apr 2026

One dose, one cure

Scientific articles
14 Apr 2026

Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis

Clinical and Translational Science
Le Monde logo
In the media
11 Apr 2026

Face à la dengue, la recherche s’active alors que le réchauffement laisse craindre une saison 2026 record

Le Monde
Scientific articles
27 Mar 2026

Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review

BMJ Public Health
News
31 Mar 2026

DNDi is looking for a Board Treasurer to join its Board of Directors

Chemistry World logo, C and W letters in a light grey on a black background
In the media
26 Mar 2026

Boron plays a key role in new sleeping sickness drug

Chemistry World
Title copy on white and orange background, picture of Fr Robinson on the right hand
Videos
26 Mar 2026

Manufacturing medicines for NTDs, with Dr Stephen Robinson

Scientific articles
14 Jan 2026

(Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance

The Lancet Microbe
Scientific articles
24 Mar 2026

The burden of eumycetoma in Africa: a neglected fungal disease

The Lancet Regional Health – Africa
Statements
23 Mar 2026

DNDi statement at the sixth meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement

TV5Monde-logo
In the media
18 Mar 2026

RD Congo : Un nouveau traitement contre la maladie du sommeil

TV5Monde
loading
Loading...
Press releases
Press Releases Translations
Researchers in lab environment
Press releases
7 Apr 2023

eWHORM project launched to eliminate worm infections in Sub Saharan Africa

Children standing in front of a house in rural village in Colombia
Press releases
4 Apr 2023

Dutch Postcode Lottery supports DNDi’s efforts to develop new treatments for children affected by neglected diseases

Patient with healthcare worker in hospital
Press releases
30 Mar 2023

Eumycetoma: DNDi welcomes Japan’s GHIT Fund support for registration of new treatment for deeply neglected fungal disease

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Researcher looking into a microscope
Press releases
14 Dec 2022

Launch of first platform for emergency research preparedness and response in Africa

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

Healthcare workers looking into microscopes
Press releases
30 Nov 2022

Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

Patient speaking with two doctors
Press releases
15 Nov 2022

Leishmaniasis project launched in Eastern Africa to improve patient access to treatments

Young boy in consultation with two doctors
Press releases
6 Oct 2022

Le Canton de Genève soutient la recherche sur le mycétome, l’une des maladies les plus négligées au monde

Lab Activities
Press releases
29 Sep 2022

Better, shorter combination treatment for people with visceral leishmaniasis shown to be effective in Eastern Africa

Dr Luis Pizarro
Press releases
5 Sep 2022

Dr Luis Pizarro becomes new Executive Director of the Drugs for Neglected Diseases initiative

Lab technician at work
Press releases
30 Aug 2022

Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and DNDi to explore joint opportunities to develop affordable and life-saving new drugs for neglected tropical diseases

Laboratory assistant conducts analysis at laboratory in Peru
Press releases
3 Aug 2022

Network of experts calls for urgent boost to research and development of rapid tests for cutaneous leishmaniasis in Latin America

Lab activities
Press releases
27 Jul 2022

Korean cutting-edge technology to reduce the cost of promising drug for neglected disease visceral leishmaniasis

Lab activities
Press releases
6 Jul 2022

Wellcome renews partnership with DNDi to develop new generation drugs to treat leishmaniasis

1 2 … 21 ›

Connect and share

Follow us on social media to stay updated and help us share the stories of neglected patients.  

Twitter Facebook Instagram Youtube Linkedin
EN ESPAÑOL
EM PORTUGUÊS
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license